ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2026
[Preliminary Analysis of Tumor Immune Microenvironment Characteristics in Lung Squamous Cell Carcinoma after Neoadjuvant Immunochemotherapy Based on Single-cell Transcriptomics].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant immunochemotherapy has emerged as an important treatment strategy for non-small cell lung cancer (NSCLC); however, substantial heterogeneity in therapeutic response persists among patients. Currently, treatment efficacy is primarily evaluated by imaging modalities, and there remains a lack of comprehensive studies investigating post-treatment alterations in the tumor microenvironment (TME) and their association with clinical response. This study applied single-cell RNA sequencing (scRNA-seq) to characterize TME remodeling in lung squamous cell carcinoma after neoadjuvant immunochemotherapy and to explore its potential association with differences in therapeutic response.
methodsTumor specimens from two patients with lung squamous cell carcinoma who underwent surgical resection following neoadjuvant immunochemotherapy were subjected to scRNA-seq. An integrated analysis was performed to characterize the cellular composition, functional states, and intercellular communication patterns within the TME.
resultsPreoperative imaging evaluation indicated partial response (PR) in patient 1 and stable disease (SD) in patient 2, whereas postoperative pathological evaluation showed major pathological response (MPR) and partial pathological response (PPR), respectively. ScRNA-seq identified nine major cell populations. The TME exhibited marked heterogeneity between the two patients: patient 1 was characterized by immune cell enrichment and inflammatory activation, whereas patient 2 showed remodeling dominated by myeloid and endothelial signals, together with more prominent immune regulatory and angiogenic features. Cell-cell communication analysis revealed that patient 1 was mainly characterized by inflammatory chemotactic interactions, whereas patient 2 showed enhanced C-X-C motif chemokine ligand (CXCL), secreted phosphoprotein 1 (SPP1), vascular endothelial growth factor (VEGF), macrophage migration inhibitory factor (MIF) and tumor necrosis factor (TNF) signaling, along with prominent immunosuppressive interaction axes. In addition, patient 2 showed a relative enrichment of macrophages and a more pronounced exhausted T-cell phenotype.
conclusionsAfter neoadjuvant immunochemotherapy, the TME in patients with lung squamous cell carcinoma exhibits marked heterogeneity in terms of cellular composition, functional states, and intercellular communication. The TME remodeling patterns revealed by scRNA-seq may provide insights into discrepancies in treatment response evaluation and help identify potential biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.